TheStreet upgraded shares of DexCom, Inc. (NASDAQ:DXCM) from a d rating to a c- rating in a research note issued to investors on Wednesday.
Several other research analysts also recently weighed in on DXCM. BMO Capital Markets restated an outperform rating and set a $90.00 price objective (down previously from $105.00) on shares of DexCom in a report on Wednesday. B. Riley restated a buy rating and set a $95.00 price objective on shares of DexCom in a report on Sunday, May 7th. BidaskClub downgraded shares of DexCom from a hold rating to a sell rating in a report on Monday, July 24th. Stephens restated an overweight rating and set a $83.00 price objective (down previously from $95.00) on shares of DexCom in a report on Wednesday. Finally, Oppenheimer Holdings, Inc. set a $92.00 price objective on shares of DexCom and gave the stock a buy rating in a report on Wednesday. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $87.00.
DexCom (NASDAQ DXCM) opened at 71.14 on Wednesday. DexCom has a 52-week low of $57.68 and a 52-week high of $96.38. The company’s market cap is $6.16 billion. The company has a 50-day moving average of $72.42 and a 200-day moving average of $75.68.
DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The firm had revenue of $170.60 million for the quarter, compared to the consensus estimate of $166.54 million. During the same quarter in the prior year, the company posted ($0.24) earnings per share. The business’s revenue was up 24.3% on a year-over-year basis. On average, equities research analysts expect that DexCom will post ($0.77) earnings per share for the current fiscal year.
In related news, EVP Steven Robert Pacelli sold 1,450 shares of the stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $69.47, for a total transaction of $100,731.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Andrew K. Balo sold 3,200 shares of the stock in a transaction dated Wednesday, May 10th. The shares were sold at an average price of $71.93, for a total transaction of $230,176.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 36,331 shares of company stock valued at $2,548,619. Company insiders own 1.70% of the company’s stock.
A number of institutional investors have recently bought and sold shares of DXCM. Livforsakringsbolaget Skandia Omsesidigt bought a new position in DexCom during the first quarter valued at $136,000. IFP Advisors Inc raised its position in DexCom by 9.3% in the first quarter. IFP Advisors Inc now owns 1,863 shares of the medical device company’s stock valued at $158,000 after buying an additional 159 shares during the last quarter. Edmond DE Rothschild Holding S.A. bought a new position in DexCom during the first quarter valued at $164,000. Mn Services Vermogensbeheer B.V. raised its position in DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock valued at $179,000 after buying an additional 83 shares during the last quarter. Finally, Independent Portfolio Consultants Inc. raised its position in DexCom by 0.4% in the second quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock valued at $183,000 after buying an additional 9 shares during the last quarter.
About DexCom
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
